Author

B. Maiorano

h-index 20 View on Semantic Scholar

We have 4 of 192 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods

Background Over the past decades, treatment of metastatic urothelial carcinoma (mUC) has been transformed by three backbone therapies: platinum-based chemotherapy (PBC), immune checkpoint inhibitors (ICIs), and antibody-drug conjugates (ADCs), used alone or in combination. Evaluating temporal trends in overall survival...

A. Cigliola, B. Maiorano, G. Guandalini et al. · ESMO Open · 0 citations

Sep 2026

Impact of Age on Outcomes in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT).

BACKGROUND Malignancies arising in young adults often exhibit biological and clinical behaviors distinct from those in older patients. Limited data exist on the prognostic impact of age in metastatic non-clear cell renal cell carcinoma (mnccRCC). This study compared survival outcomes by age using the large-scale TriNet...

A. Cigliola, Nazli Dizman, C. Mercinelli et al. · Clinical Genitourinary Cance... · 0 citations

Review Open access Aug 2026

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group

Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...

A. A. Valsecchi, M. Maffezzoli, M. Cursano et al. · Cancer Metastasis Review · 0 citations

#explainable ai Sep 2026

Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study.

Preliminary, hypothesis-generating findings suggest ML may predict EV-related toxicities, but single train-test split, small event counts, and lack of external validation preclude clinical use.

K. Sridharan, Mattia Alberto Di Civita, G. Sivaramakrishnan et al. · Expert Review of Anticancer... · 0 citations